An AI scribe platform that automatically generates clinical notes for doctors during consultations, reducing administrative burden.
Company context
Lyrebird Health prompts can include culture, product, and business context from this profile.
Role targeting
Pair this profile with an open role to generate focused behavioral and technical questions.
Answer coaching
Practice responses, get feedback, and refine stories before applying or interviewing.
Lyrebird Health is an Australian health-tech startup that provides an AI-powered ambient clinical documentation platform designed to alleviate the administrative burden on healthcare professionals. By recording and transcribing patient-doctor consultations in real-time, the platform automatically generates structured clinical notes that integrate directly into existing Electronic Medical Record (EMR) systems. This technology allows clinicians to focus more on patient care rather than paperwork, significantly reducing the time spent on documentation during and after consultations. Founded in 2023 by Kai Van Lieshout and Linus Talacko, the company has rapidly scaled to become a prominent player in the Australian digital health market. With a focus on clinical accuracy and data privacy, Lyrebird Health has secured significant venture capital funding and established strategic partnerships with major healthcare institutions both in Australia and internationally. The company continues to expand its footprint by prioritizing seamless integration with clinical workflows and maintaining strict compliance with medical data standards.
Lyrebird Health’s mission is to reduce the administrative burden on clinicians so they can focus on what truly matters: their patients.
Founded
2023
Headquarters
Melbourne, Australia
Employees
11-50
Industry
Digital Health
High impact work that directly reduces clinician burnout
Fast-paced startup environment with significant growth potential
High pressure environment typical of early-stage, high-growth startups
Rapidly evolving product requirements due to the nature of AI development
Funding
$12 million
CEO
Kai Van Lieshout